Sintilimab plus bevacizumab before surgery for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests two drugs, sintilimab and bevacizumab, given before surgery to treat liver cancer that can be removed. It's for people with a certain stage of liver cancer who haven't had other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults 18 or older with a type of liver cancer called hepatocellular carcinoma (HCC) that can be surgically removed (resectable) and is beyond the Milan criteria.
- You must not have had any previous treatment for your liver cancer.
- Your liver function must be good (Child-Pugh class A) and you should be in relatively good health (performance status 0-1).
- No history of bleeding from your stomach or esophagus (varices), blood clots, or uncontrolled high blood pressure.
- You cannot have other active cancers, serious infections, or autoimmune diseases requiring treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (sintilimab), a targeted anti-angiogenic drug (bevacizumab biosimilar), and liver-directed therapies (TACE-HAIC) before and after surgery for hepatocellular carcinoma that has spread to the portal vein. The goal is to see if this approach improves outcomes for patients with advanced but resectable liver cancer.
This trial tests whether giving an immunotherapy drug (sintilimab) after surgery helps keep liver cancer with microscopic blood vessel invasion from coming back. It may improve chances of staying cancer-free after surgery.
This trial tests a new drug combination (ZG005 plus bevacizumab) against a standard combination (sintilimab plus bevacizumab) in people with advanced liver cancer that has spread or cannot be surgically removed. The goal is to see which combination works better and is safe.
This trial tests whether giving two medicines (an immunotherapy and a targeted therapy) after surgery can help prevent liver cancer from coming back in people with a specific type of tumor clot in the liver's main vein. If you've had surgery to remove the cancer and meet the health criteria, this treatment may lower your risk of recurrence.
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
This trial tests giving two immunotherapy drugs directly into the tumor before surgery for liver cancer. It aims to see if this approach can shrink the tumor and improve outcomes for patients who are candidates for surgery.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.